<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04088331</url>
  </required_header>
  <id_info>
    <org_study_id>U0669</org_study_id>
    <nct_id>NCT04088331</nct_id>
  </id_info>
  <brief_title>Artificial Urinary Sphincter Clinical Outcomes</brief_title>
  <acronym>AUSCO</acronym>
  <official_title>Artificial Urinary Sphincter Clinical Outcomes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Scientific Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boston Scientific Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the AMS 800 Artificial Urinary Sphincter (AUS) in men with primary stress urinary&#xD;
      incontinence as measured by pad weight tests.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 14, 2019</start_date>
  <completion_date type="Anticipated">August 2023</completion_date>
  <primary_completion_date type="Anticipated">August 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of subjects with reduction in 24 hour pad weight test at 12 months</measure>
    <time_frame>12 months</time_frame>
    <description>Number of subjects achieving 50% reduction or greater in baseline urinary incontinence as measured by 24-hour pad weight test at 12 months post device activation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of safety parameters</measure>
    <time_frame>3 months, 6 months and 12 months</time_frame>
    <description>Incidence of safety parameters at 3 months, 6 months, and 12 months. Safety parameters include device and/or procedure related adverse events, revision rates, and serious adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects achieving ≥ 50% reduction in 24 hour pad weight test at 6 months</measure>
    <time_frame>Device Activation and 6 months</time_frame>
    <description>Number of subjects achieving ≥ 50% reduction in urinary incontinence as measured by 24-hour pad weight test at device activation and 6 months post device activation compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects achieving ≥ 75% reduction in 24 hour pad weight test at 6 and 12 months</measure>
    <time_frame>Device Activation, 6 months, and 12 months</time_frame>
    <description>≥ 75% reduction in urinary incontinence as measured by 24-hour pad weight test at device activation, 6 months, and 12 months post device activation compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of pads per day</measure>
    <time_frame>3 months, 6 months, and 12 months</time_frame>
    <description>Reduction in # of pads per day at 3 months, 6 months and 12 months post-device activation compared to baseline</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">175</enrollment>
  <condition>Stress Urinary Incontinence</condition>
  <arm_group>
    <arm_group_label>AMS 800 Artificial Urinary Sphincter Recipients</arm_group_label>
    <description>Adult males with moderate to severe primary stress urinary incontinence (as assessed by a baseline pad weight test) due to ISD who meet the indications for surgical correction of urinary incontinence.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>AMS 800 Artificial Urinary Sphincter</intervention_name>
    <description>The AMS 800 Artificial Urinary Sphincter (AUS) is an implantable, fluid filled, solid silicone elastomer device used to treat stress urinary incontinence due to reduced urethral/bladder outlet resistance (intrinsic sphincter deficiency). It is designed to restore the natural process of urinary control. The device simulates normal sphincter function by opening and closing the urethra under the control of the patient.</description>
    <arm_group_label>AMS 800 Artificial Urinary Sphincter Recipients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        This study will enroll adult males with moderate to severe primary stress urinary&#xD;
        incontinence (as assessed by a baseline pad weight test) due to ISD who meet the&#xD;
        indications for surgical correction of urinary incontinence.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male&#xD;
&#xD;
          2. ≥ 18 years of age&#xD;
&#xD;
          3. Has undergone either a radical prostatectomy, transurethral resection of the prostate&#xD;
             or other invasive prostate surgery&#xD;
&#xD;
          4. Demonstrates primary stress urinary incontinence&#xD;
&#xD;
          5. Positive screening 24-hour pad weight test (≥100 grams)&#xD;
&#xD;
          6. Experiences at least 3 incontinence episodes per day during baseline diary or presents&#xD;
             with continuous incontinence&#xD;
&#xD;
          7. Negative urine culture&#xD;
&#xD;
          8. Willing and able to undergo surgical implantation of the AUS device&#xD;
&#xD;
          9. Willing and able to comply with the follow-up requirements&#xD;
&#xD;
         10. Willing and able to forego any other surgical urinary incontinence treatments while&#xD;
             participating in the study&#xD;
&#xD;
         11. Willing and able to sign the informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Previously had or currently has a device implanted (AUS/Sling, or otherwise) for&#xD;
             treatment of SUI or urge incontinence&#xD;
&#xD;
          2. Primary urgency incontinence&#xD;
&#xD;
          3. History of adjuvant or neo-adjuvant radiation therapy, cryotherapy, or high-intensity&#xD;
             focused ultrasound therapy&#xD;
&#xD;
          4. Postvoid residual volume greater that 150 ml or a history of difficulty emptying the&#xD;
             bladder&#xD;
&#xD;
          5. Recurrent vesicourethral anastomotic stricture or urethral stricture disease within&#xD;
             the past 6 months&#xD;
&#xD;
          6. Known urogenital malignancy other than previously treated prostate cancer&#xD;
&#xD;
          7. Recurrent prostate cancer that is expected to require intervention during the study&#xD;
             follow-up period&#xD;
&#xD;
          8. History of recurrent bladder stones within the past 12 months prior to signing the&#xD;
             informed consent&#xD;
&#xD;
          9. Neurogenic bladder&#xD;
&#xD;
         10. Need for intermittent catheterization&#xD;
&#xD;
         11. Known history of bleeding diathesis or coagulopathy&#xD;
&#xD;
         12. Immunosuppressed or on medical therapy which would impact the immune system&#xD;
&#xD;
         13. Uncontrolled diabetes, defined as (HbA1c&gt;10)&#xD;
&#xD;
         14. Has a genitourinary mechanical prosthesis&#xD;
&#xD;
         15. Undergone bulking procedure within 6 months of the baseline assessment&#xD;
&#xD;
         16. Poor candidate for surgical procedures and/or anesthesia due to physical or mental&#xD;
             conditions&#xD;
&#xD;
         17. Urinary incontinence due to or complicated by an irreversibly obstructed lower urinary&#xD;
             tract&#xD;
&#xD;
         18. Irresolvable detrusor hyperreflexia or bladder instability&#xD;
&#xD;
         19. Currently enrolled or plans to enroll in another device or drug clinical trial&#xD;
&#xD;
         20. Currently using an indwelling catheter or condom catheter for treatment of&#xD;
             incontinence and is not willing to discontinue use at least 4 weeks prior to baseline&#xD;
             assessment&#xD;
&#xD;
         21. Known allergy or sensitivity to rifampin or to minocycline HCl or other tetracyclines&#xD;
             (only applicable when implanting with InhibiZone version of this device)&#xD;
&#xD;
         22. Systemic lupus erythematosus because minocycline HCl has been reported to aggravate&#xD;
             this condition (only applicable when implanting with InhibiZone version of this&#xD;
             device)&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Melissa Kaufman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt Urology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amanda J Vail, MPH</last_name>
    <phone>612-749-5366</phone>
    <email>amanda.vail@bsci.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anthony Enriquez</last_name>
      <phone>415-206-8805</phone>
      <email>anthony.enriquez2@ucsf.edu</email>
    </contact>
    <investigator>
      <last_name>Benjamin Breyer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Iowa Hospitals and Clinics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Denise Juhr</last_name>
      <phone>319-356-1111</phone>
      <email>denise-juhr@uiowa.edu</email>
    </contact>
    <investigator>
      <last_name>Bradley Erickson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Kansas Hospital</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160-7234</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katie Glavin</last_name>
      <phone>913-588-8721</phone>
      <email>kglavin@kumc.edu</email>
    </contact>
    <investigator>
      <last_name>Joshua Broghammer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Willis-Knighton Bossier Medical Center</name>
      <address>
        <city>Bossier City</city>
        <state>Louisiana</state>
        <zip>71111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carrie Kay</last_name>
      <phone>318-212-8130</phone>
      <email>ckay@wkhs.com</email>
    </contact>
    <investigator>
      <last_name>Gerard Henry, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heather Lyons</last_name>
      <phone>410-955-0937</phone>
      <email>hlyons5@jhmi.edu</email>
    </contact>
    <investigator>
      <last_name>Arthur Burnett, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lahey Clinic Hospital</name>
      <address>
        <city>Burlington</city>
        <state>Massachusetts</state>
        <zip>01805</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Linda Topijan</last_name>
      <phone>781-744-8711</phone>
      <email>linda.m.topjian@lahey.org</email>
    </contact>
    <investigator>
      <last_name>Alex Vanni, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Minnesota Medical Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Siobhan O'Toole</last_name>
      <phone>612-625-3319</phone>
      <email>otool098@umn.edu</email>
    </contact>
    <investigator>
      <last_name>Sean Elliott, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frederica Gallack</last_name>
      <phone>919-681-5557</phone>
      <email>fredrica.gallack@duke.edu</email>
    </contact>
    <investigator>
      <last_name>Andrew Peterson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wake Forest University School of Medicine</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sachin Vyas, Ph.D.</last_name>
      <phone>336-713-4098</phone>
      <email>svyas@wakehealth.edu</email>
    </contact>
    <investigator>
      <last_name>Ryan Terlecki, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Barbara Tucky</last_name>
      <phone>216-444-1044</phone>
      <email>tuckyb@ccf.org</email>
    </contact>
    <investigator>
      <last_name>Hadley Wood, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pamela Steele</last_name>
      <phone>615-343-2120</phone>
      <email>pamela.steele@vumc.org</email>
    </contact>
    <investigator>
      <last_name>Niels Johnsen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marisa Lozano</last_name>
      <phone>713-563-7458</phone>
      <email>mllozano@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Thomas G Smith, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Methodist Hospital Research Institute</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hamida Rajab</last_name>
      <phone>713-363-9154</phone>
      <email>hrajab@houstonmethodist.org</email>
    </contact>
    <investigator>
      <last_name>Timothy Boone, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Urology San Antonio Research, PA.</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hannah Sherman</last_name>
      <phone>210-617-4116</phone>
      <email>hannah.sherman@urologysa.com</email>
    </contact>
    <investigator>
      <last_name>Leroy Jones, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth Lignell</last_name>
      <phone>801-213-2718</phone>
      <email>elizabeth.lignell@hsc.utah.edu</email>
    </contact>
    <investigator>
      <last_name>Jeremy Myers, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>September 10, 2019</study_first_submitted>
  <study_first_submitted_qc>September 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 12, 2019</study_first_posted>
  <last_update_submitted>November 2, 2021</last_update_submitted>
  <last_update_submitted_qc>November 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Incontinence</mesh_term>
    <mesh_term>Urinary Incontinence, Stress</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

